Core Viewpoint - Hutchison China MediTech (00013) saw a stock increase of over 5%, reaching HKD 24.68 with a trading volume of HKD 112 million, following the announcement of upcoming data presentations at major oncology conferences in 2025 [1] Group 1: Upcoming Events - The company will present updated research data on its proprietary compounds at the 2025 World Lung Cancer Conference (WCLC) in Barcelona from September 6 to 9, and at the 2025 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Jinan, China, from September 10 to 14 [1] Group 2: Research Highlights - The latest analysis results of the SACHI and SAVANNAH studies, as well as a Phase IIIb confirmatory study of Savolitinib for non-small cell lung cancer, will be disclosed at the WCLC [1] - HMPL-653, a novel selective and potent CSF-1R inhibitor, will have its first human Phase I clinical trial data in Chinese patients with tenosynovial giant cell tumors presented at the CSCO annual meeting [1]

Core Insights - Hutchison China MediTech Limited (Chi-Med) will present updated data on several of its self-developed compounds at the 2025 World Lung Cancer Conference (WCLC) in Barcelona and the 2025 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Jinan, China [1] Group 1: Upcoming Conferences - The 2025 WCLC will take place from September 6 to 9 in Barcelona, Spain [1] - The 2025 CSCO Annual Meeting will be held from September 10 to 14 in Jinan, China [1] Group 2: Research Highlights - The latest analysis results of the SACHI and SAVANNAH studies, as well as a Phase IIIb confirmatory study of Savolitinib for treating non-small cell lung cancer, will be presented at the WCLC [1] - Savolitinib is a potent, highly selective oral MET tyrosine kinase inhibitor (TKI) co-developed by AstraZeneca and Chi-Med, with commercialization by AstraZeneca [1] - Data from the first human Phase I clinical trial of HMPL-653, a novel, selective, and potent CSF-1R inhibitor, in patients with tenosynovial giant cell tumors will be presented for the first time at the CSCO Annual Meeting [1]

Core Viewpoint - Hutchison China MediTech Limited (和黄医药) will present updated research findings on its self-developed compounds at two major conferences in 2025, highlighting its ongoing commitment to advancing cancer treatment [1] Group 1: Upcoming Conferences - The 2025 World Lung Cancer Conference (WCLC) will take place in Barcelona, Spain from September 6 to 9, 2025 [1] - The 2025 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) will be held in Jinan, China from September 10 to 14, 2025 [1] Group 2: Research Focus - The latest analysis results of the SACHI study, SAVANNAH study, and an Ib phase validation study on Savolitinib for treating non-small cell lung cancer will be presented at the WCLC [1] - Savolitinib is described as a potent and highly selective oral MET tyrosine kinase inhibitor (TKI), co-developed by AstraZeneca and Hutchison China MediTech, with commercialization handled by AstraZeneca [1]

Core Insights - Hutchison China MediTech Limited (HCM) will present updated data on its proprietary compounds at two major conferences in September 2025, specifically the World Lung Cancer Conference (WCLC) in Barcelona and the Chinese Society of Clinical Oncology (CSCO) annual meeting in Jinan, China [1] Group 1: Upcoming Presentations - HCM will showcase the latest analysis results of the SACHI and SAVANNAH studies, as well as a Phase IIIb confirmatory study of Savolitinib for the treatment of non-small cell lung cancer at the WCLC [1] - The first human Phase I clinical trial data for HMPL-653, a novel selective and potent CSF-1R inhibitor, will be presented at the CSCO annual meeting [1] Group 2: Drug Development - Savolitinib is described as a potent and highly selective oral MET tyrosine kinase inhibitor (TKI), co-developed by AstraZeneca and HCM, with AstraZeneca responsible for commercialization [1]

Core Insights - HUTCHMED will present new and updated data from several studies at the 2025 World Conference on Lung Cancer (WCLC) and the Chinese Society of Clinical Oncology (CSCO) Annual Meeting [1][2][3] Group 1: WCLC Presentations - Updated analysis from savolitinib's studies, including SACHI, SAVANNAH, and a Phase IIIb confirmatory study in non-small cell lung cancer (NSCLC) patients, will be presented [2] - Specific presentations include: - "Biomarker Concordance and Acquired Resistance in Patients with EGFRm MET-OverExp and/or Amp NSCLC" by Christina Baik on September 7, 2025 [2] - "Efficacy and Safety of Savolitinib in Advanced or Metastatic METex14 NSCLC Patients With or Without Prior Immunotherapy" by Yongfeng Yu on September 9, 2025 [2] - Insights from the SACHI study regarding frontline treatment duration in MET-Amplified NSCLC after third-generation EGFR-TKI failure [2] Group 2: CSCO Annual Meeting Presentations - Clinical data of HMPL-653, a novel CSF-1R inhibitor, will be presented for the first time at the CSCO Annual Meeting [3] - Specific presentations include: - A first-in-human Phase I study of HMPL-653 in patients with tenosynovial giant cell tumor by Xiaohui Niu on September 12, 2025 [3] - Updated efficacy and safety data for Fruquintinib in various cancer types, including metastatic or unresectable non-clear cell renal cell carcinoma and advanced esophageal squamous cell carcinoma [3][4] Group 3: Company Overview - HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on the discovery and global development of targeted therapies and immunotherapies for cancer and immunological diseases [5] - The company has successfully marketed its first three medicines in China, with the first also approved in the US, Europe, and Japan [5]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不 對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 HUTCHMED (China) Limited 和黃醫藥（中國）有限公司 （於開曼群島註冊成立的有限公司） （股份代號：13） | 摘要標題 | 報告人/ 主要作者 | 報告詳情 | | --- | --- | --- | | 研究者發起的研究 | | | | 索凡替尼、度伐利尤單抗聯合化療用於一線治療廣泛期小細胞肺癌的療效及 | 張卉/ 胡瑛，北京胸科 | P3.13.22 | | 安全性 | 醫院，中國北京 | 海報展示 Poster: Small Cell Lung | | Efficacy and Safety of Surufatinib, Durvalumab in Combined with | | Cancer and Neuroendocrine | | Chemotherapy as First-line Treatment of Extensive-stage Small-cell ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 和黃醫藥（中國）有限公司 呈交日期: 2025年9月1日 II. 已發行股份及/或庫存股份變動 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00013 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,500,000,000 | USD | | 0.1 USD | | | 150,000,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | | | | 本月底結存 | | | 1,500,000,000 | USD | | 0.1 USD | | | 1 ...

Core Viewpoint - The announcement from Hutchison China MediTech Limited (HutchMed) regarding the temporary suspension of its CEO due to health reasons and the appointment of the CFO as acting CEO [1] Company Summary - HutchMed's board has acknowledged that the CEO, Su Weiguo, will pause his duties for health reasons [1] - The board has appointed Zheng Zefeng, the executive director and CFO, to serve as the acting CEO effective immediately [1]

Group 1 - The Shanghai Science and Technology Awards 2024 recognized a total of 206 awards, including various categories such as the Shanghai Science and Technology Progress Award and the Shanghai International Science and Technology Cooperation Award [1] - Among the award recipients, 1,171 individuals under the age of 45 accounted for 65% of the total, indicating a growing recognition of young scientists in Shanghai's innovation landscape [2] - The number of enterprises involved in award-winning projects reached 336, representing 49% of all completion units, with a notable increase in participation from private enterprises [3] Group 2 - The focus on technology transfer and industrial application is emphasized, with 34 projects directly mentioning "application," making up 54% of high-level award-winning results [4] - The Shanghai government is actively promoting the construction of an international technology innovation center, supporting both state-owned and private enterprises in innovation and development [5] - The success of young scientists and enterprises is seen as a vital source of innovation for Shanghai's technological ecosystem [6]

Group 1 - The core viewpoint of the article highlights a significant decline in innovative drug concept stocks in Hong Kong, with notable drops in companies such as Innovent Biologics (5.3% decrease), CStone Pharmaceuticals (3.72% decrease), and others [1] - U.S. President Trump's announcement to reduce drug prices to 1/1400 to 1/1500 of current prices and impose tariffs on drugs could create turbulence in the global pharmaceutical industry, presenting both opportunities and challenges for Chinese biopharmaceutical stocks [1] - Morgan Stanley's report suggests that the likelihood of tariffs on outbound licensing cooperation (BD) payments is low, as current U.S. tariffs primarily target tangible goods and focus on production repatriation, with service-related revenues, including intellectual property transfers, receiving less attention [1] Group 2 - The majority of BD agreements include granting development and manufacturing rights to global licensors, with some licensors planning to produce approved licensed drugs locally in the U.S. after receiving approval [1]